You are here

  • Home
  • Archive
  • Volume 17, Issue 6
  • Screening for postmenopausal osteoporosis with any modality is cost-effective including screening initiation at 55 years of age

Article Text

Article menu
Download PDFPDF
Economic analysis
Screening for postmenopausal osteoporosis with any modality is cost-effective including screening initiation at 55 years of age
  1. Gavin Clunie
  1. Department of Rheumatology, The Ipswich Hospital, Ipswich, UK
  1. Correspondence to: Gavin Peter Ross Clunie
    Department of Rheumatology, The Ipswich Hospital, Heath Rd, Ipswich, Suffolk IP4 5PD, UK; gavin.clunie{at}doctors.org.uk
View Full Text

http://dx.doi.org/10.1136/ebmed-2012-100779

Statistics from Altmetric.com

    Commentary on: Nayak S, Roberts MS, Greenspan SL. Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. Ann Intern Med 2011;155:751–61.OpenUrlCrossRefPubMedWeb of Science

    Context

    Postmenopausal osteoporosis (PMO) related fractures are common, preventable and costly. Their prevention is a goal for healthcare agencies worldwide. Data to support screening of women are however weak and controversy surrounds whether to screen and, if so, at what age? The recommendation for, and justification of, resources for screening depends importantly on the cost-effectiveness of any screening method compared with alternatives including no screening.

    The cost-effectiveness of screening needs to be considered within a complex landscape of medicosocial, financial and practical issues relevant to the healthcare system in which it operates. Accordingly, this analysis by Nayak et al is the most comprehensive attempt to date, to model the costs of screening for PMO.

    Methods

    The models estimated the costs (US$) of various screening methods …

    View Full Text

    Footnotes

    • Competing interests None.

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions